Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
Revive Therapeutics (RVVTF) has acquired DiagnaMed's molecular hydrogen intellectual property through an asset purchase agreement dated March 31, 2025. The acquisition, valued at $50,000, will be satisfied through the issuance of one million common shares at $0.05 per share.
The acquired assets include a provisional patent application for pharmaceutical-based methods using molecular hydrogen to treat neurological and mental health disorders, including Dementia, Parkinson's disease, Traumatic brain injury, Depression, Anxiety, and Post-traumatic stress disorder. Additionally, the acquisition includes research activities and an FDA Orphan Drug Designation (ODD) for molecular hydrogen in treating ALS.
ALS affects approximately 50,000 people in the U.S. and Europe, with over 5,000 new cases diagnosed annually. The disease has a life expectancy of two to six years after diagnosis, with no known cure currently available.
Revive Therapeutics (RVVTF) ha acquisito la proprietà intellettuale dell'idrogeno molecolare di DiagnaMed tramite un accordo di acquisto di beni datato 31 marzo 2025. L'acquisizione, del valore di 50.000 dollari, sarà soddisfatta attraverso l'emissione di un milione di azioni ordinarie a 0,05 dollari per azione.
Gli asset acquisiti includono una domanda di brevetto provvisorio per metodi farmacologici che utilizzano l'idrogeno molecolare per trattare disturbi neurologici e di salute mentale, tra cui Demenza, malattia di Parkinson, trauma cranico, depressione, ansia e disturbo da stress post-traumatico. Inoltre, l'acquisizione include attività di ricerca e una Designazione di Farmaco Orfano della FDA (ODD) per l'idrogeno molecolare nel trattamento della SLA.
La SLA colpisce circa 50.000 persone negli Stati Uniti e in Europa, con oltre 5.000 nuovi casi diagnosticati annualmente. La malattia ha un'aspettativa di vita di due a sei anni dopo la diagnosi, senza alcuna cura nota attualmente disponibile.
Revive Therapeutics (RVVTF) ha adquirido la propiedad intelectual de hidrógeno molecular de DiagnaMed a través de un acuerdo de compra de activos fechado el 31 de marzo de 2025. La adquisición, valorada en 50,000 dólares, se llevará a cabo mediante la emisión de un millón de acciones ordinarias a 0.05 dólares por acción.
Los activos adquiridos incluyen una solicitud de patente provisional para métodos farmacéuticos que utilizan hidrógeno molecular para tratar trastornos neurológicos y de salud mental, incluyendo Dementia, enfermedad de Parkinson, lesión cerebral traumática, depresión, ansiedad y trastorno de estrés postraumático. Además, la adquisición incluye actividades de investigación y una Designación de Medicamento Huérfano de la FDA (ODD) para el hidrógeno molecular en el tratamiento de la ELA.
La ELA afecta a aproximadamente 50,000 personas en EE. UU. y Europa, con más de 5,000 nuevos casos diagnosticados anualmente. La enfermedad tiene una expectativa de vida de dos a seis años tras el diagnóstico, sin cura conocida actualmente disponible.
Revive Therapeutics (RVVTF)는 2025년 3월 31일 자산 구매 계약을 통해 DiagnaMed의 분자 수소 지적 재산을 인수했습니다. 인수 가치는 50,000달러로, 주당 0.05달러의 가격으로 100만 주의 보통주를 발행하여 충족됩니다.
인수된 자산에는 분자 수소를 사용하여 신경학적 및 정신 건강 장애를 치료하는 제약 기반 방법에 대한 임시 특허 출원이 포함되어 있으며, 여기에는 치매, 파킨슨병, 외상성 뇌손상, 우울증, 불안 및 외상 후 스트레스 장애가 포함됩니다. 또한, 인수에는 ALS 치료를 위한 분자 수소에 대한 FDA 희귀의약품 지정(ODD)이 포함됩니다.
ALS는 미국과 유럽에서 약 50,000명에게 영향을 미치며, 매년 5,000건 이상의 새로운 사례가 진단됩니다. 이 질병은 진단 후 2~6년의 기대 수명을 가지며, 현재 알려진 치료법은 없습니다.
Revive Therapeutics (RVVTF) a acquis la propriété intellectuelle de l'hydrogène moléculaire de DiagnaMed par le biais d'un accord d'achat d'actifs daté du 31 mars 2025. L'acquisition, d'une valeur de 50 000 dollars, sera réalisée par l'émission d'un million d'actions ordinaires à 0,05 dollar par action.
Les actifs acquis comprennent une demande de brevet provisoire pour des méthodes pharmaceutiques utilisant l'hydrogène moléculaire pour traiter des troubles neurologiques et de santé mentale, y compris Démence, maladie de Parkinson, traumatisme crânien, dépression, anxiété et trouble de stress post-traumatique. De plus, l'acquisition inclut des activités de recherche et une Désignation de médicament orphelin de la FDA (ODD) pour l'hydrogène moléculaire dans le traitement de la SLA.
La SLA touche environ 50 000 personnes aux États-Unis et en Europe, avec plus de 5 000 nouveaux cas diagnostiqués chaque année. La maladie a une espérance de vie de deux à six ans après le diagnostic, sans traitement connu actuellement disponible.
Revive Therapeutics (RVVTF) hat das geistige Eigentum von DiagnaMed für molekularen Wasserstoff durch einen am 31. März 2025 datierten Vermögensübertragungsvertrag erworben. Die Akquisition hat einen Wert von 50.000 Dollar und wird durch die Ausgabe von einer Million Stammaktien zu je 0,05 Dollar pro Aktie erfüllt.
Die erworbenen Vermögenswerte umfassen einen vorläufigen Patentantrag für pharmazeutische Methoden, die molekularen Wasserstoff zur Behandlung von neurologischen und psychischen Erkrankungen verwenden, darunter Demenzi, Parkinson-Krankheit, traumatische Hirnverletzung, Depression, Angstzustände und posttraumatische Belastungsstörung. Darüber hinaus umfasst die Akquisition Forschungsaktivitäten und eine FDA-Waisenmedikamentenbezeichnung (ODD) für molekularen Wasserstoff zur Behandlung von ALS.
ALS betrifft etwa 50.000 Menschen in den USA und Europa, mit über 5.000 neuen Fällen, die jährlich diagnostiziert werden. Die Krankheit hat eine Lebenserwartung von zwei bis sechs Jahren nach der Diagnose, wobei derzeit kein bekanntes Heilmittel verfügbar ist.
- FDA Orphan Drug Designation obtained for molecular hydrogen in ALS treatment
- Expansion into neurological and mental health disorders market
- No additional financial obligations (milestones, royalties) beyond initial purchase price
- Access to patent-pending technology for multiple high-value indications
- Share dilution through issuance of 1 million new shares
- Early-stage technology without proven clinical efficacy
- No immediate revenue generation potential
TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that further to its press release dated March 3, 2025, it has entered into an asset purchase agreement (the “Agreement”) dated March 31, 2025 with DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) (“DiagnaMed”) to acquire the full rights to DiagnaMed’s intellectual property (the “Acquired Assets”) pertaining to molecular hydrogen as potential treatments for neurological and mental health disorders (the “Acquisition”).
Pursuant to the Agreement, the consideration for the Acquired Assets will be satisfied through the issuance to DiagnaMed of one million common shares of Revive, at an issue price of
The Acquired Assets will include all of the following:
- Provisional patent application with the U.S. Patent and Trademark Office outlining pharmaceutical-based methods and compositions for producing molecular hydrogen as potential treatments for neurological and mental health disorders. The patent application, entitled “Methods and Compositions for Producing Hydrogen for Treating Diseases and Disorders Affecting Brain Health,” outlines novel combinations of certain pharmaceutical-grade hydrogen producing ingredients as a potential therapeutic option for a variety of neurological disorders such as, but not limited to, Dementia, Parkinson’s disease, and Traumatic brain injury, and mental health disorders including, Depression, Anxiety, and Post-traumatic stress disorder (press release).
- All intellectual and work property derived from DiagnaMed’s research activities in amyotrophic lateral sclerosis (ALS) and its Orphan Drug Designation (ODD) for molecular hydrogen in the treatment of ALS by the U.S. Food and Drug Administration (FDA).
Michael Frank, CEO of Revive, commented: “This acquisition expands Revive’s pipeline to brain disorders. Molecular hydrogen may offer a potential therapeutic option for neurological and mental health disorders. The orphan drug designation granted by the FDA for molecular hydrogen in ALS offers hope to patients and families impacted by this debilitating illness. We are committed to collaborating with leading ALS researchers, patient advocacy groups, and regulatory experts to ensure a rigorous and expedited path toward potential approval.”
ALS is a progressive neuromuscular disease that attacks nerve cells responsible for controlling voluntary muscle movement, leading to paralysis and, ultimately, respiratory failure, and has a life expectancy of only two to six years after diagnosis. Currently, there is no known cure for ALS. ALS affects approximately 50,000 people in the U.S. and Europe, with over 5,000 new cases diagnosed annually. With limited treatment options available, the FDA’s recognition of molecular hydrogen as an orphan drug offers hope to patients and families impacted by this debilitating illness.
Molecular hydrogen, a small molecule with antioxidant and anti-inflammatory properties, has shown early promise in preclinical studies for its ability to mitigate oxidative stress and inflammation—key factors implicated in ALS progression. The FDA’s decision paves the way for Revive to accelerate its development programs with molecular hydrogen.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three and six months ended December 31, 2024 ("MD&A"), dated February 24, 2025, which is available on the Company's profile at www.sedarplus.ca.
FAQ
What assets did Revive Therapeutics (RVVTF) acquire in the molecular hydrogen program purchase?
How much did Revive Therapeutics (RVVTF) pay for the molecular hydrogen program acquisition?
What medical conditions will RVVTF target with the acquired molecular hydrogen technology?
What is the market size for ALS treatment that RVVTF is targeting?
